NCT06807632View on ClinicalTrials.gov

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Valemetostat

"Dose level -1 100 mg po once daily~Dose level 1 150 mg po once daily~Dose level 2 200 mg po once daily"

DRUG

Atezolizumab

1680 mg IV q4weeks

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER